Aspergillosis, the leading fungal cause of mortality in immunocompromised patients, presents a serious worldwide challenge--particularly in the face of increasing antifungal resistance. Bringing together the world's leaders in the Aspergillus and aspergillosis fields to promote cross-disciplinary collaboration among clinicians, industry, and scientific experts, the "Advances Against Aspergillosis" conference was held January 26-28, 2012 in Istanbul, Turkey.
This first of two Annals volumes contains short reviews encapsulating recent clinical findings on aspergillosis. Among the topics included are the application of diagnostic markers to invasive aspergillosis in children, risk stratification for invasive aspergillosis in immunocompromised patients, use of biological agents for the treatment of fungal asthma and allergic bronchopulmonary aspergillosis, immune regulation in idiopathic bronchiectasis, and management of chronic pulmonary aspergillosis.
NOTE: Annals volumes are available for sale as individual books or as a journal. For information on institutional journal subscriptions, please visit: http: //ordering.onlinelibrary.wiley.com/subs.asp?ref=1749-6632&doi=10.111/(ISSN)1749-6632.
ACADEMY MEMBERS: Please contact the New York Academy of Sciences directly to place your order (www.nyas.org). Members of the New York Academy of Science receive full-text access to Annals online and discounts on print volumes. Please visit http: //www.nyas.org/MemberCenter/Join.aspx for more information on becoming a member.
About the Author: Karl V Clemons, Stanford University, Stanford, California.
Malcolm Richardson, University of Manchester, Manchester, United Kingdom.
David S Perlin, UMDNJ-New Jersey Medical School, Newark, New Jersey.
